30 PENHALLOW STREET, SUITE 400,
PORTSMOUTH , NH, 03801

Rank

Rank Universe

Summary

The fund seeks to provide total return that replicate the price and yield performance of the benchmark index before fees and expenses by investing in mid-and large-size companies outside the United States.

The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.

The fund employs a passiv More

Link

Directors

Mar 11, 2024
  • John L. Liechty
  • D'Anne Hurd
  • Gregory D. Sheehan
  • Lindsey Brace Martinez
  • Nancy S. Taylor
  • Adrian P. Anderson
  • Anne M. Goggin
  • Joseph Keefe

Chief Compliance Officer

  • JOHN BOESE

Fund Manager(s)

Price

  • $ 10.74 ( +0.01 )
    Nov 1, 2024
    Last Close
  • Net Assets
  • $1.1B
    Feb 20, 2024
  • Holding
  • 136
    Aug 23, 2024
    More

  • 52-Week High/Low
  • $11.6 - $8.79
  • Turnover
  • 51%
  • Expense Ratio
  • 0.47%

Company Name

Holding

Novo Nordisk A/S 3.4 %
ASML Holding NV 2.98 %
AstraZeneca plc 2.69 %
Novartis AG 2.65 %
HSBC Holdings plc 2.36 %
Schneider Electric SE 2.25 %
CSL Ltd. 2.03 %
BNP Paribas SA 1.91 %
RELX plc 1.9 %
Tokyo Electron Ltd. 1.87 %
More 1.87 %

Documents

Prospectus

Annual Reports

Fact Sheet

Q3 2021 Q2 2021

Performance

YTD

1.9%

3 Year

-4.19%

5 Year

17.76%

Best

39.65%

2009

Worst

-19.98%

2022

Alpha

PXNIX S&P 500

Chart +